Every investor in VBI Vaccines Inc. (NASDAQ:VBIV) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership.

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Jul 25, 2016) - VBI Vaccines Inc. (VBIV)(VBV.TO) ("VBI") is pleased to announce the appointment of Dr. Francisco Diaz-Mitoma, M.D., Ph.D., as Chief Medical ...

- Presentation title: “Long-Term Persistence of Anti-HBs Antibodies after Vaccination with a 3-Antigen HBV Vaccine Compared with a Single-Antigen HBV Vaccine” Timo Vesikari, M.D., Ph.D., Professor ...

Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) VBI-2601 (BRII-179) was ...

After trimming its headcount last year in an effort to cut down on operational expenses, VBI Vaccines found another way to improve its financial position with an up to $33 million Brii Biosciences ...

There's no question that the biggest reason to consider buying shares of VBI remains the potential for Sci-B-Vac. The vaccine has already been approved in Israel. VBI announced positive results from a ...

VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate ...

GlaxoSmithKline (GSK) will partner with VBI Vaccines to study VBI’s LPV™ Platform, a formulation and process designed to help develop vaccines and biologics with improved stability and potency. The ...

VBI's coronavirus vaccine candidate, VBI-2901, is still in preclinical development, meaning that it is significantly less advanced than those of companies such as Moderna (MRNA 8.00%). Nonetheless, ...

SciVac Therapeutics has agreed to acquire VBI Vaccines in a $92 million stock deal that will create a vaccine-focused developer with a licensed hepatitis B (HBV) vaccine and a pipeline of preventive ...

VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate ...